Jaguar8 commented on a stock · Nov 20, 2024 21:08

NEWS

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo Holdings (NASDAQ:ONVO)presented Phase 2 clinical trial results for FXR314 at The Liver Meeting. The study involved 214 MASH patients randomized to receive 3mg, 6mg FXR314, or placebo. The drug demonstrated statistically significant liver fat reduction from baseline: 22.8% (3mg) and 17.5% (6mg) versus 6.1% placebo. Notably, >30% MRI-PDFF reduction was achieved in 29.2% (3mg) and 32.2% (6mg) of subjects compared to 9.5% with placebo. FXR314 showed improved safety profile with lower pruritus rates (2.8-4.2%) compared to other FXR agonists, and minimal LDL-C level changes.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

3195 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8166

Followers

Following

93K

Visitors